TC
IONS icon

Trilogy Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Trilogy Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37
Closed -$2K – 340
2018
Q3 		$2K Hold
37
– – ﹤0.01% 500
2018
Q2 		$2K Hold
37
– – ﹤0.01% 464
2018
Q1 		$2K Buy
+37
New +$1.88K ﹤0.01% 389

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Trilogy Capital's IONS Position: Q4 2018 in Review

Trilogy Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 37 shares — an estimated $2K sold.

Trilogy Capital first reported a position in IONS in Q1 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

  • Trilogy Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Trilogy Capital sold 37 Ionis Pharmaceuticals shares in Q4 2018, an estimated $2K.
  • Trilogy Capital first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Trilogy Capital's Ionis Pharmaceuticals position peaked at $2K in Q3 2018.
  • 329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.